Protara Therapeutics, Inc.
TARANext catalyst
TARA-002
Non-muscle Invasive Bladder Cancer
Get an email about TARA's next catalysts
Track Protara Therapeutics (TARA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
TARA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.37 | FQ end Sep/2026 | Call: tbd
TARA-002 Phase 2 Est. Readout (STARBORN-1)
Estimated primary completion for TARA-002 trial (NCT05871970) in Lymphatic Malformation. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Choline Chloride for Injection
Choline Deficiency
TARA-002
Non-muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Choline Chloride for Injection | Phase 3 | Choline Deficiency | - | - |
TARA-002 | Phase 3 | Non-muscle Invasive Bladder Cancer | - | - |
Frequently asked questions
What is in Protara Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Protara Therapeutics, Inc.'s (TARA) pipeline across Phase 3. Its lead program is TARA-002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Protara Therapeutics, Inc.'s next FDA catalyst?→
Protara Therapeutics, Inc.'s (TARA) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TARA biotech catalysts?→
Add TARA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Protara Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.